This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ISIS 2302; AP 1007
Description: Alicaforsen is an antisense inhibitor of intercellular adhesion molecule-1 (ICAM-1), an important mediator of inflammation.
Deal Structure: In March 2007, Isis licensed alicaforsen to Atlantic Healthcare (UK) Limited. Atlantic Healthcare plans to initially develop alicaforsen for pouchitis, an ulcerative colitis indication, followed by ulcerative colitis and other inflammatory diseases. In exchange for the exclusive, worldwide license to alicaforsen, Isis will receive an upfront payment from Atlantic Healthcare in the form of equity valued at $2 million. In addition, assuming Atlantic Healthcare successfully develops and commercializes alicaforsen, Isis will receive milestone payments and royalties on future product sales of alicaforsen. If Atlantic Healthcare meets certain of these milestones, at Atlantic Healthcares request, Isis will attempt to identify a second generation lead drug candidate for Atlantic Healthcare. Atlantic Healthcare may take an exclusive worldwide license to the lead candidate under the terms and conditions of the agreement. Atlantic Healthcare is solely responsible for the continued development...See full deal structure in Biomedtracker
Partners: Ionis Pharmaceuticals, Inc.
Additional information available to subscribers only: